Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer
Ian E. Krop, Thomas M. Suter, Chau T. Dang, Luc Dirix, Gilles Romieu, Claudio Zamagni, Marc L. Citron, Mario Campone, Na Xu, Melanie Smitt, and Luca Gianni
Onco Targets Ther. 2015 Jun 5;8:1341-3. doi: 10.2147/OTT.S84480. eCollection 2015.
ABSTRACT
Erlotinib, an epidermal growth factor receptor and tyrosine kinase inhibitor, is a targeted drug that was approved for the treatment of non-small-cell lung cancers and pancreatic cancers. Targeted tyrosine kinase inhibitors are known to have cardiotoxic effects. However, erlotinib does not have a statistically proven effect of increasing acute cardiovascular event (ACE) risk. Preclinical studies showed that beta agonist stimulation among rats that were administered erlotinib led to cardiovascular damage. Thus, there would be an aggregate effect of erlotinib on ACE, although it is not thought to be a cardiotoxic drug itself. In this paper, we present two non-small-cell lung cancer cases that developed ACE under erlotinib treatment.
fonte: http://www.ft-patho.net/index.php?HER2%20-%20human%20epidermal%20growth%20factor%20receptor%202